ATE220719T1 - Cytokin -, stress - und oncogen - aktivierte kinasen der humanen proteinkinasen - Google Patents

Cytokin -, stress - und oncogen - aktivierte kinasen der humanen proteinkinasen

Info

Publication number
ATE220719T1
ATE220719T1 AT96905233T AT96905233T ATE220719T1 AT E220719 T1 ATE220719 T1 AT E220719T1 AT 96905233 T AT96905233 T AT 96905233T AT 96905233 T AT96905233 T AT 96905233T AT E220719 T1 ATE220719 T1 AT E220719T1
Authority
AT
Austria
Prior art keywords
stress
oncogenic
cytokine
protein kinases
human protein
Prior art date
Application number
AT96905233T
Other languages
English (en)
Inventor
Roger J Davis
Shashi Gupta
Joel Raingeaud
Benoit Derijard
Original Assignee
Roger J Davis
Shashi Gupta
Joel Raingeaud
Benoit Derijard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/446,083 external-priority patent/US5804427A/en
Application filed by Roger J Davis, Shashi Gupta, Joel Raingeaud, Benoit Derijard filed Critical Roger J Davis
Application granted granted Critical
Publication of ATE220719T1 publication Critical patent/ATE220719T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736Retinoblastoma protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
AT96905233T 1995-05-19 1996-01-26 Cytokin -, stress - und oncogen - aktivierte kinasen der humanen proteinkinasen ATE220719T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/446,083 US5804427A (en) 1995-05-19 1995-05-19 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US08/530,950 US5736381A (en) 1995-05-19 1995-09-19 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
PCT/US1996/001078 WO1996036642A1 (en) 1995-05-19 1996-01-26 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Publications (1)

Publication Number Publication Date
ATE220719T1 true ATE220719T1 (de) 2002-08-15

Family

ID=27034496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905233T ATE220719T1 (de) 1995-05-19 1996-01-26 Cytokin -, stress - und oncogen - aktivierte kinasen der humanen proteinkinasen

Country Status (11)

Country Link
US (6) US5736381A (de)
EP (2) EP0830374B1 (de)
JP (1) JP3948571B2 (de)
AT (1) ATE220719T1 (de)
AU (1) AU710877B2 (de)
CA (1) CA2219487A1 (de)
DE (1) DE69622405T2 (de)
DK (1) DK0830374T3 (de)
ES (1) ES2179178T3 (de)
PT (1) PT830374E (de)
WO (1) WO1996036642A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US6074862A (en) * 1995-12-20 2000-06-13 Signal Pharmaceuticals Inc. Mitogen-activated protein kinase kinase MEK6 and variants thereof
US6699983B1 (en) 1995-12-21 2004-03-02 Sunnybrook Health Sciences Centre Integrin-linked kinase and its uses
US6013782A (en) * 1995-12-21 2000-01-11 Sunnybrook Health Sciences Center Integrin-linked kinase and its uses
US6001622A (en) 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US7863429B2 (en) 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
NZ322401A (en) 1995-12-21 2000-02-28 Sunnybrook Health Science Ct Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy, and pseudo-substrate inhibitors
AU736316B2 (en) * 1996-05-20 2001-07-26 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6677130B1 (en) 1996-05-20 2004-01-13 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US5948885A (en) * 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
DE69731964T2 (de) 1996-10-09 2005-12-08 Medical Research Council Map-kinase: polypeptide, polynukleotide und ihre verwendung
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
GB9717416D0 (en) * 1997-08-19 1997-10-22 Medical Res Council Polypeptides,polynucleotides and uses thereof
US6943000B2 (en) 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
US6492112B1 (en) 1997-12-31 2002-12-10 Chiron Corporation Mitogen-activated protein kinase kinase 7 (MKK7)
US6312934B1 (en) * 1998-03-16 2001-11-06 National Jewish Center For Immunology And Respiratory Medicine Human MEKK proteins, corresponding nucleic acid molecules, and uses therefor
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
CA2327351A1 (en) * 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Cell signaling proteins
US6096543A (en) * 1998-11-20 2000-08-01 Isis Pharmaceuticals Inc. Antisense inhibition of human mek1 expression
US6033910A (en) * 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
US6010906A (en) * 1999-07-21 2000-01-04 Isis Pharmaceuticals Inc. Antisense modulation of Jun N-terminal kinase kinase-1 expression
US6376747B1 (en) * 1999-08-27 2002-04-23 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Plant-derived map kinase kinase
EP1224463A2 (de) * 1999-10-08 2002-07-24 Superarray, Inc. Kompositionen und verfahrens zum nachweis eiweismodifikation und enzymaktivität
JP2003530110A (ja) * 2000-04-10 2003-10-14 スージェン・インコーポレーテッド 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素
AU2001266611A1 (en) * 2000-06-01 2001-12-11 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
US6824989B1 (en) * 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6498035B1 (en) * 2000-09-08 2002-12-24 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK3 expression
CA2431904A1 (en) 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
WO2002064025A2 (en) * 2001-02-15 2002-08-22 Mount Sinai School Of Medicine Of New York University Inhibition of atf2 activity to treat cancer
EP2135611A1 (de) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yn-3,7,17-triol Derivate zur therapeutischen Verwendung
WO2003023362A2 (en) * 2001-09-12 2003-03-20 The Regents Of The University Of California Methods of ameliorating arthritis by modulating jnk signalsome activity
GB0224013D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
US20060281699A1 (en) * 2004-05-12 2006-12-14 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2006029470A1 (en) * 2004-09-17 2006-03-23 Walsh, Barbara Casual personnel recruitment method and system
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
CA2693694A1 (en) * 2007-06-08 2008-12-11 University Of Massachusetts Mixed lineage kinases and metabolic disorders
US20120077753A1 (en) 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
EP4374863A3 (de) 2014-12-18 2024-09-04 President and Fellows of Harvard College Verfahren zur erzeugung von beta-zellen aus stammzellen und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5981265A (en) * 1993-04-15 1999-11-09 National Jewish Center For Immunology And Respiratory Medicine Methods for regulating MEKK protein activity
WO1995028421A1 (en) * 1993-04-15 1995-10-26 National Jewish Center For Immunology And Respiratory Medicine Method and product for regulating cell responsiveness to external signals
SE503628C2 (sv) * 1994-07-05 1996-07-22 Vikthygien Ab Mätdon
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Also Published As

Publication number Publication date
US6174676B1 (en) 2001-01-16
DE69622405T2 (de) 2003-03-27
JP2002503946A (ja) 2002-02-05
US20090053231A1 (en) 2009-02-26
EP1251177A3 (de) 2003-04-23
AU710877B2 (en) 1999-09-30
US6541605B1 (en) 2003-04-01
JP3948571B2 (ja) 2007-07-25
AU4904696A (en) 1996-11-29
EP1251177A2 (de) 2002-10-23
WO1996036642A1 (en) 1996-11-21
EP0830374A1 (de) 1998-03-25
US5736381A (en) 1998-04-07
EP0830374B1 (de) 2002-07-17
DK0830374T3 (da) 2002-10-28
US20050272077A1 (en) 2005-12-08
EP0830374A4 (de) 1998-10-07
PT830374E (pt) 2002-11-29
ES2179178T3 (es) 2003-01-16
DE69622405D1 (de) 2002-08-22
CA2219487A1 (en) 1996-11-21
US20020102691A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
ATE220719T1 (de) Cytokin -, stress - und oncogen - aktivierte kinasen der humanen proteinkinasen
DE68929475D1 (de) Wässrige Copolymer-Dispersion zur Lederbehandlung
ES2015511A4 (es) Collarin cervical ajustable.
NO880185L (no) Individuelt justerbart putesystem.
DK345488A (da) Azolylmethyl-cyclopropyl-derivater, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK20690A (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
DE68907406D1 (de) Deprenyl zur systemischen transdermalen anwendung.
BR9406485A (pt) Aparelho para o ajuste de nivel e/ou para o ajuste do arqueamento de um elemento de suporte flexivel elastico de um encosto de um assento
DK120188A (da) Aminomethylheterocycler, fremgangsmaader til deres fremstilling samt deres anvendelse
DE69724457D1 (de) Vorrichtung zur korrektur und zur stabilisierung der abweichenden krümmung einer wirbelsäule
DE69629968D1 (de) Vorrichtung zur Stimulation der Herzfunktion
DE3788773D1 (de) Vorrichtung zur Feinverstellung und Vorrichtung zum Steuern dieser Verstellungen.
DE3874199D1 (de) Einrichtung zur polarisationssteuerung.
DE69833946D1 (de) Durch cytokine, stress und oncoproteine aktivierte kinasen von menschlicher proteinkinase
DE68927342D1 (de) Zeitweiliger tintenbehälter und schreibinstrument unter dessen verwendung
DE68915010D1 (de) Schreibkopfsteuergerät.
DK88989D0 (da) Substituerede pyrimidiner, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse
DE3870197D1 (de) Verstellbare justiervorrichtung.
DK494589A (da) Substituerede 1,3,5-triazintrioner og deres anvendelse samt mellemprodukter til deres fremstilling
DK384588D0 (da) Substituerede triazolinoner, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DE68911784D1 (de) Druckabhängige und elektrisch gesteuerte Durchflussmengenregelvorrichtung.
DK436388D0 (da) Substituerede pyrimidiner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK378488D0 (da) Anellerede iminoazoler og iminoaziner, fremgangsmaade til fremstilling heraf og deres anvendelse med herbicid virkning
DE58908586D1 (de) Tauchtiefengesteuerte Ausblasventil-Einrichtung.
DK144989A (da) Disubstituerede pyrroler, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0830374

Country of ref document: EP

REN Ceased due to non-payment of the annual fee